Sara Bonstein
Director of Finance/CFO at INSMED INCORPORATED
Net worth: 3 M $ as of 31/03/2024
Profile
Sara M.
Bonstein is an Independent Director at scPharmaceuticals, Inc., Xilio Therapeutics, Inc., and a Chief Financial Officer at Insmed, Inc. She previously worked as a Director-Development Finance at ImClone LLC from 2004 to 2014, Finance Director at Eli Lilly & Co., CFO, Secretary, Treasurer & Executive VP at Advaxis, Inc. from 2014 to 2018, and Secretary, Chief Operating & Financial Officer at OncoSec Medical, Inc. from 2018 to 2020.
She holds an undergraduate degree from The College of New Jersey and an MBA from Rider University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
INSMED INCORPORATED
0.08% | 09/01/2024 | 114,051 ( 0.08% ) | 3 M $ | 31/03/2024 |
SCPHARMACEUTICALS, INC.
-.--% | 29/02/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Sara Bonstein active positions
| Companies | Position | Start |
|---|---|---|
| INSMED INCORPORATED | Director of Finance/CFO | 31/01/2020 |
| SCPHARMACEUTICALS INC. | Director/Board Member | 08/07/2020 |
| XILIO THERAPEUTICS, INC. | Director/Board Member | 17/08/2021 |
Former positions of Sara Bonstein
| Companies | Position | End |
|---|---|---|
| ONCOSEC MEDICAL INCORPORATED | Director of Finance/CFO | 30/01/2020 |
| AYALA PHARMACEUTICALS, INC. | Director of Finance/CFO | 30/04/2018 |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Corporate Officer/Principal | 01/02/2014 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Training of Sara Bonstein
| The College of New Jersey | Undergraduate Degree |
| Rider University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 5 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| INSMED INCORPORATED | Health Technology |
| ONCOSEC MEDICAL INCORPORATED | Health Services |
| SCPHARMACEUTICALS INC. | Health Technology |
| XILIO THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Health Technology |
Advaxis, Inc.
 Advaxis, Inc. Pharmaceuticals: MajorHealth Technology Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ. | Health Technology |
- Stock Market
- Insiders
- Sara Bonstein
